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Using a humanized mouse model, we developed melanoma specific CD8 T cells from genetically modified human
hematopoietic stem cells (hHSC). The transgenic T cells were functional both in vivo and ex vivo, effectively limiting and
clearing tumor growth. Finally, the transduced hHSC stably populated the bone marrow.
The human immune system is a formid-
able weapon against cancer and immune-
based therapies have been used to combat
this chronic disease. Such therapies include
the adoptive transfer of tumor specific
autologous T cells or the introduction of
tumor specific T-cell receptors (TcR) via
lentiviral vectors into peripheral blood
T cells, which has been used with some
success in melanoma.
1,2 The introduction
of exogenous TcR into mature T cells
while promising harbors the risk of
generating autoreactive clones
3 and results
in T-cell exhaustion due to the ex vivo
manipulation required for the transduc-
tion of these cells.
4 These limitations can
be addressed by introducing the exogenous
TcR into hematopoietic progenitor cells,
which would then differentiate into
mature tumor specific T cells. Such an
approach allows for the proper maturation
and selection of the transgenic T cells and,
due to the self-renewing nature of stem
cells, can result in a long-term and stable
source of tumor specific T cells.
5
The recent advancements in humanized
mouse models have made it possible to
address this approach in vivo. For our
studies, we used an adaptation of the bone
marrow/liver/thymus (BLT) humanized
mouse model.
6 In this model, fetal human
thymus combined with fetal liver is
transplanted under the kidney capsule of
the immunodeficient NSG (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) mouse. This
is followed by sublethal irradiation and
transplantation of autologous human
hematopoietic stem cells (hHSC). The
outcome is full reconstitution of the
immune system with human cells.
7,8
Furthermore, the hHSC can be genetically
modified and give rise to engineered
functional mature lymphocytes (modified
BLT).
8 Thus, this model was the most
appropriate system to examine in vivo both
the generation and the functionality of
melanoma-specific transgenic CD8 T cells
(CTL) against human tumor challenge.
To this end we used the modified BLT
to assess whether we can in vivo generate
and assess MART-1 specific CTL. We
constructed a lentiviral vector encoding
the F5 MART-1 TcR, an HLA-A*0201-
restricted melanoma-specific TcR, and
optimized herpes simplex virus 1 thymi-
dine kinase (sr39tk) gene which serves
both as a PET reporter and a suicide gene.
The vector was introduced into HLA-
A*0201
+ hHSC, which were combined
with autologous fetal thymic tissue to
make the thy/liv implant. A second
fraction of the transduced hHSC was then
used for transplantation 3 weeks later.
Approximately 4–6 weeks after hHSC
transplantation, we assessed reconstitution
of MART-1 transgenic CTL in the murine
circulation. We detected high levels of
mature transgenic CTL that maintained a
naïve phenotype (based on expression of
CD62L and CD27). The MART TcR was
rarely detected on CD4 T cells suggesting
that the proper T-cell selection and lineage
commitment took place. To confirm that
the selection was taking place in the thy/liv
implant and not the mouse thymus, we
tested the above approach on an HLA-
A*0201
- background. We did not detect
any CD8 or CD4 T cell expressing the
TcR in the periphery.
Following reconstitution with the trans-
genic CTL, the chimeric mice were chal-
lenged with the human melanoma tumor
lines M202, an HLA-A*0201
+MART
+ cell
line that could serve as a target for the
transgenic CTL, and M207, an HLA-
A*0201
-MART
+ line that could not. The
tumors were implanted on the left (M202)
and right (M207) mouse shoulder. Tumor
regression was assessed by both physical
measurements and PET imaging (Fig.1).
PET imaging proved particularly beneficial
andquiteeffectiveinassessingtheefficacyof
the transgenic CTL. The physical measure-
ments, while demonstrating decreasing
tumor sizes, were masked in some occasions
by tissue scarring or “dead space” due to
tissue necrosis caused by the anti-tumor
immune response resulting in the appear-
anceoffalsepositivetumorgrowth.Thus,at
the endpoint of our experiment (about
12 weeks after hHSC transplantation), we
used PET imaging for [
18F]FDG uptake to
measuretumormetabolicactivitybyglucose
uptake. The data revealed that in 7/9 mice
we had targeting of the M202 tumor with
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4/9 miceshowing complete tumorclearance
(Fig.1). There was some limited regression
in the M207 control tumors potentially due
to bystander activation of an allogeneic
response. Lastly, we detected increased
infiltration of MART CTLs into the
M202 tumors.
Further ex vivo analysis of the trans-
genic CTLs revealed that these cells had
undergone the appropriate antigen induced
maturation. Splenocytes from the treated
mice effectively killed the M202 targets
in a CTL killing assay in the absence of
any additional activation. When compared
with cells from control mice (mice
receiving non transduced hHSC), which
were predominantly naive, the trans-
genic MART CTLs from spleen were
comprised of naïve (CD45RA
+CCR7
+),
central (CD45RA
-CCR7
+), effector
(CD45RA
-CCR7
-) memory and terminally
differentiated (CD45RA
+CCR7
-) cells.
Finally, our data showed a correlation
between tumor metabolic activity and
levels of reconstitution or ex vivo cytolytic
activity.
As stated earlier, this approach would
be advantageous due to the longevity of
hHSC. This would result in the con-
tinuous production of MART-1 specific
CTL, thus maintaining a high precursor
frequency to control tumor growth and/or
relapse. We collected bone marrow cells
from the treated and control chimeras and
detected the presence of the lentiviral
vector (by real time PCR) and the
expression of the sr39tk reporter (by flow
cytometry).
In summary, the impact of our studies
is 2-fold. First, we demonstrate as a proof
of principle that functional tumor specific
CTLs can be generated from genetically
modified human hematopoietic progeni-
tors. Second, we have developed a model
that can be utilized to explore a wide span
of alternative or combination treatments
against cancer and chronic diseases.
9
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Figure1. MART-1 specific CTL limit and clear growth of matched melanoma tumors. In vivo PET
imaging was performed to assess the levels of FDG uptake by the M202 and M207 tumors.
The circles indicate the location of the M202 (right) and M207 (left) tumors.
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